
TY  - JOUR
TI  - Abstracts of the BAUS Annual Meeting: Harrogate, UK, 21-25 June, 2004
JO  - BJU International
VL  - 93
IS  - s4
SN  - 1464-4096
UR  - https://doi.org/10.1111/j.1464-410X.2004.04853.x
DO  - doi:10.1111/j.1464-410X.2004.04853.x
SP  - 1
EP  - 116
PY  - 2004
ER  - 

TY  - JOUR
TI  - Original Research Clinical
JO  - Oral Diseases
VL  - 18
IS  - s1
SN  - 1354-523X
UR  - https://doi.org/10.1111/j.1601-0825.2012.12005_2.x
DO  - doi:10.1111/j.1601-0825.2012.12005_2.x
SP  - 10
EP  - 34
PY  - 2012
ER  - 

TY  - JOUR
AU  - Maki, Robert G.
TI  - Pediatric sarcomas occurring in adults
JO  - Journal of Surgical Oncology
JA  - J. Surg. Oncol.
VL  - 97
IS  - 4
SN  - 0022-4790
UR  - https://doi.org/10.1002/jso.20969
DO  - doi:10.1002/jso.20969
SP  - 360
EP  - 368
KW  - Ewing sarcoma
KW  - desmoplastic small round cell tumor
KW  - osteogenic sarcoma
KW  - rhabdomyosarcoma
KW  - chemotherapy
PY  - 2008
AB  - Abstract Sarcomas arise in any part of the body, in any age group. Some sarcomas have a particular predilection for the pediatric population, and often bear specific chromosomal translocations. These ?pediatric? sarcomas still occur in adults, often times with higher risk of dying of disease compared to children with a comparable diagnosis. The management of some of these rare tumors is discussed herein, including osteogenic sarcoma, Ewing sarcoma, and rhabdomyosarcoma. J. Surg. Oncol. 2008;97:360?368. ? 2008 Wiley-Liss, Inc.
ER  - 

TY  - JOUR
TI  - International Society of Paediatric Oncology SIOP 2007: Contents and Abstracts
JO  - Pediatric Blood & Cancer
JA  - Pediatr. Blood Cancer
VL  - 49
IS  - 4
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.21342
DO  - doi:10.1002/pbc.21342
SP  - 398
EP  - 605
PY  - 2007
AB  - Abstract The Full online issue can be found at http://www.interscience.wiley.com/jpages/1545-5009/suppmat
ER  - 

TY  - JOUR
TI  - Concurrent Session 2: Monday 20 April Afternoon
JO  - Journal of Paediatrics and Child Health
JA  - J Paediatr Child Health
VL  - 51
IS  - S1
SN  - 1034-4810
UR  - https://doi.org/10.1111/jpc.12884_2
DO  - doi:10.1111/jpc.12884_2
SP  - 17
EP  - 35
PY  - 2015
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Journal of Thrombosis and Haemostasis
JA  - J Thromb Haemost
VL  - 14
IS  - S1
SN  - 1538-7933
UR  - https://doi.org/10.1111/jth.13325
DO  - doi:10.1111/jth.13325
SP  - 1
EP  - 168
PY  - 2016
ER  - 

TY  - JOUR
AU  - Wu, Yuxuan
AU  - Wang, Lei
AU  - Bao, Hanmo
AU  - Zou, Shenshan
AU  - Fu, Chunling
AU  - Gong, Hui
AU  - Gao, Yong
AU  - Tang, Yuan
AU  - Yu, Rutong
AU  - Shi, Hengliang
TI  - Nrdp1S, short variant of Nrdp1, inhibits human glioma progression by increasing Nrdp1-mediated ErbB3 ubiquitination and degradation
JO  - Journal of Cellular and Molecular Medicine
JA  - J. Cell. Mol. Med.
VL  - 20
IS  - 3
SN  - 1582-1838
UR  - https://doi.org/10.1111/jcmm.12735
DO  - doi:10.1111/jcmm.12735
SP  - 422
EP  - 429
KW  - Nrdp1
KW  - Nrdp1S
KW  - ubiquitination
KW  - ErbB3
KW  - glioma
PY  - 2016
AB  - Abstract The ubiquitin ligase neuregulin receptor degradation protein 1 (Nrdp1) is involved in the induction of apoptosis and suppression of tumour formation. We previously showed that it was expressed at lower levels in human glioma tissues compared with normal brain tissues. However, the mechanism underlying this is unclear. Here, we reported that a novel short variant (Nrdp1S), lacking 71 amino acids at the N-terminal, was expressed in normal human brain tissue, but absent from glioma tissues. Similar to Nrdp1, Nrdp1S could be degraded by the proteasomal pathway, but exhibited an even longer half-life than Nrdp1. Nrdp1S was also shown to form a heterodimer with Nrdp1, which increased its stability, thereby augmenting the Nrdp1-mediated ubiquitination and degradation of ErbB3. EdU incorporation, MTT assay and in vitro colony formation demonstrated that Nrdp1S significantly inhibited the cell tumourigenicity. These results together suggest that Nrdp1S is a tumour suppressor that which potentiates the Nrdp1-mediated ubiquitination and degradation of ErbB3. An Nrdp1S deficiency may also be an important factor in the loss of Nrdp1.
ER  - 

TY  - JOUR
TI  - The International Liver Transplantation Society, 13th Annual International Congress, June 20–23, 2007, Rio de Janeiro, Brazil
JO  - Liver Transplantation
JA  - Liver Transpl
VL  - 13
IS  - S1
SN  - 1527-6465
UR  - https://doi.org/10.1002/lt.21269
DO  - doi:10.1002/lt.21269
SP  - S1
EP  - S238
PY  - 2007
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Fundamental & Clinical Pharmacology
VL  - 22
IS  - s1
SN  - 0767-3981
UR  - https://doi.org/10.1111/j.1472-8206.2008.00575.x
DO  - doi:10.1111/j.1472-8206.2008.00575.x
SP  - 1
EP  - 102
PY  - 2008
ER  - 

TY  - JOUR
TI  - ICS 2017 Abstracts
JO  - Neurourology and Urodynamics
JA  - Neurourol. Urodynam.
VL  - 36
IS  - S3
SN  - 0733-2467
UR  - https://doi.org/10.1002/nau.23386
DO  - doi:10.1002/nau.23386
SP  - S1
EP  - S575
PY  - 2017
AB  - Watch ICS 2017 Abstract Videos Online
ER  - 

TY  - JOUR
AU  - Wechalekar, Ashutosh D.
AU  - Gillmore, Julian D.
AU  - Bird, Jenny
AU  - Cavenagh, Jamie
AU  - Hawkins, Stephen
AU  - Kazmi, Majid
AU  - Lachmann, Helen J.
AU  - Hawkins, Philip N.
AU  - Pratt, Guy
AU  - the BCSH Committee
TI  - Guidelines on the management of AL amyloidosis
JO  - British Journal of Haematology
JA  - Br J Haematol
VL  - 168
IS  - 2
SN  - 0007-1048
UR  - https://doi.org/10.1111/bjh.13155
DO  - doi:10.1111/bjh.13155
SP  - 186
EP  - 206
KW  - amyloid
KW  - AL amyloidosis
KW  - guidelines
KW  - chemotherapy
KW  - transplantation
PY  - 2015
ER  - 

TY  - JOUR
TI  - 2011 ASPHO Abstracts
JO  - Pediatric Blood & Cancer
JA  - Pediatr. Blood Cancer
VL  - 56
IS  - 6
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.23092
DO  - doi:10.1002/pbc.23092
SP  - 897
EP  - 973
PY  - 2011
ER  - 

TY  - JOUR
AU  - Sasaki, Atsushi
AU  - Yokoo, Hideaki
AU  - Tanaka, Yuko
AU  - Homma, Taku
AU  - Nakazato, Yoichi
AU  - Ohgaki, Hiroko
TI  - Characterization of microglia/macrophages in gliomas developed in S-100β-v-erbB transgenic rats
JO  - Neuropathology
JA  - Neuropathology
VL  - 33
IS  - 5
SN  - 0919-6544
UR  - https://doi.org/10.1111/neup.12015
DO  - doi:10.1111/neup.12015
SP  - 505
EP  - 514
KW  - glioma
KW  - microglia
KW  - transgenic rats
KW  - tumor-associated macrophages
KW  - v-erbB
PY  - 2013
AB  - Glioma-infiltrating microglia/macrophages are referred to as tumor-associated macrophages (TAMs). Transgenic (TG) rats expressing v-erbB, which is a viral form of the epidermal growth factor receptor, under transcriptional regulation by the S100-? promoter, develop brain tumors. This study was designed to clarify the pathological characteristics of TAMs in these experimental tumors. We carried out immunohistochemical and morphometrical analyses of microglia/macrophages in brain tumors (5 malignant glioma, 4 anaplastic oligodendroglioma, 4 astrocytoma) that developed in TG rats. TAMs with ionized calcium-binding adaptor molecule 1 (Iba1) positivity and morphology of activated, non-phagocytic microglia increased within and around the tumors in malignant gliomas and anaplastic astrocytomas. The Iba1-positive TAMs of the tumor core were significantly more activated than Iba1-positive microglia of non-neoplastic brain tissue in intraparenchymal anaplastic oligodendrogliomas. Iba1 expression showed a significant positive correlation to Ki-67 expression in all the gliomas. Most TAMs showed no or little expression against CD68, CD163 or CD204, although CD204-positive TAMs were observed in necrosis as well as in the proliferating vascular wall. In conclusion, S-100?-v-erbB?TG rats may serve as a useful animal model for further analysis of TAMs in terms of tumor cell proliferation, microvascular proliferation and phagocytosis, and as a tool for therapeutic use in malignant gliomas, although it should be noted that the polarization of TAMs toward the M2 phenotype remains unclear.
ER  - 

TY  - JOUR
TI  - Hemodialysis Abstracts from the 36th Annual Dialysis Conference February 27–March 1, 2016 Seattle, Washington
JO  - Hemodialysis International
JA  - Hemodial Int
VL  - 20
IS  - 1
SN  - 1492-7535
UR  - https://doi.org/10.1111/hdi.12392
DO  - doi:10.1111/hdi.12392
SP  - 134
EP  - 183
PY  - 2016
ER  - 

TY  - JOUR
TI  - Poster Sessions
JO  - Allergy
JA  - Allergy
VL  - 68
IS  - s97
SN  - 0105-4538
UR  - https://doi.org/10.1111/all.12252
DO  - doi:10.1111/all.12252
SP  - 498
EP  - 636
PY  - 2013
ER  - 

TY  - JOUR
TI  - DrugScan Series
JO  - Journal of Pharmacy Practice and Research
JA  - Journal of Pharmacy Practice and Research
VL  - 41
IS  - 1
SN  - 1445-937X
UR  - https://doi.org/10.1002/j.2055-2335.2011.tb00070.x
DO  - doi:10.1002/j.2055-2335.2011.tb00070.x
SP  - 62
EP  - 72
PY  - 2011
AB  - This review brings you up-to-date with the international literature on therapeutics. Leading pharmacy practitioners scan major peer-reviewed journals in areas relevant to Australian pharmacy practice and present precis on major clinical trials, important pharmacoepidemiology studies, and pharmacoeconomic research. Interested readers are encouraged to explore the original publications in greater detail.
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - The FEBS Journal
VL  - 277
IS  - s1
SN  - 1742-464X
UR  - https://doi.org/10.1111/j.1742-4658.2010.07680.x
DO  - doi:10.1111/j.1742-4658.2010.07680.x
SP  - 37
EP  - 271
PY  - 2010
ER  - 

TY  - JOUR
AU  - Liu, Yuxin
AU  - Jia, Qi
AU  - Zhou, Jing
C7  - 1800055
TI  - Recent Advance in Near-Infrared (NIR) Imaging Probes for Cancer Theranostics
JO  - Advanced Therapeutics
JA  - Adv. Therap.
VL  - 1
IS  - 8
UR  - https://doi.org/10.1002/adtp.201800055
DO  - doi:10.1002/adtp.201800055
SP  - 1800055
KW  - cancer theranostics
KW  - luminescence
KW  - near-infrared II
KW  - photoacoustic
KW  - photothermal
PY  - 2018
AB  - Abstract With the advantages of low biofluid scattering and minimal absorbance, light in a second near-infrared window (NIR II, 1000?1700 nm) either as a signal or as an excitation source is preferred for bioimaging and disease diagnosis, especially for cancer theranostics. Due to recent advances in chemical synthesis and imaging techniques, various NIR II probes have been evaluated for tumor luminescence image-guided cancer therapy and surgery. Furthermore, probes emitting optical, acoustic, or thermal signals under NIR II excitation have also been developed for upconversion luminescence, photoacoustic, and photothermal imaging of tumors. Herein, recent advances in the use of NIR II imaging probes in cancer theranostic applications are summarized along with future perspectives.
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Fundamental & Clinical Pharmacology
JA  - Fundam Clin Pharmacol
VL  - 27
IS  - s1
SN  - 0767-3981
UR  - https://doi.org/10.1111/fcp.12026
DO  - doi:10.1111/fcp.12026
SP  - 46
EP  - 127
PY  - 2013
ER  - 

TY  - JOUR
TI  - The 46th Annual Meeting of the Japanese Society of Neuropathology
JO  - Neuropathology
VL  - 25
IS  - 2
SN  - 0919-6544
UR  - https://doi.org/10.1111/j.1440-1789.2005.00625.x
DO  - doi:10.1111/j.1440-1789.2005.00625.x
SP  - A1
EP  - A64
PY  - 2005
AB  - Date: 12?14 May 2005 Tochigi Prefectural Center President: Imaharu Nakano Plenary Lectures (P), Symposia (S) and Workshops (W) I: 1st day (12 May), II: 2nd day (13 May), III: 3rd day (14 May) O-A,O-B,O-C: Hall for Oral Session P-A,P-B,P-C: Hall for Poster Session
ER  - 
